This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Illinois officials recently released the Annual Cannabis Report for Fiscal Year 2024. The focus of the subsequent three meetings was the examination of conditions under consideration for addition to the list of debilitating conditions that are qualifying for participation in the Medical Cannabis Patient Program (MCPP).
Illinois officials recently released the Annual Cannabis Report for Fiscal Year 2024. IDFPR is also committed to working with those who received Conditional Adult Use Dispensing Organization licenses in 2023’s Social Equity Criteria Lottery to open their doors as new dispensaries and begin serving customers.
MCAB members voted to recommend Uterine Fibroid and Painful Uterine Fibroid but did not recommend Generalized Anxiety as a qualifying debilitating condition. After back-and-forth discussion, board members first voted 7-0 to approve Uterine Fibroid as a qualifying debilitating condition. Subieta Benito abstained from the vote.
December 2022, I published a 6-part series titled, “What Illinois cannabis patients really want” to start a dialogue about the large gap between patients’ needs, wishes, concerns, and recommendation for improving the Medical Cannabis Patient Program (MCPP) and the actual amendments to the law legislators have introduced.
Fernando Fandio-Sende has had countless conversations with patients with autoimmune conditions. We’re aware that each person’s medical condition presents unique challenges with can be deeply personal. Dr. Sende offers Medical Marijuana recommendations for patients with one of Floridas qualifying conditions.
The Decline of Medical Marijuana in Massachusetts: What It Means for Patients In recent years, Massachusetts, once a pioneer in cannabis reform, has seen its medical marijuana program gradually overshadowed by the booming recreational market. Let’s explore how this shift occurred and its implications for patients.
Part I of this series detailed the difficult, time consuming, and courageous work behind the process of how the Illinois Department of Public Health (IDPH) added female orgasmic disorder to the list of qualifying debilitating condition for medical patients in the Compassionate Use of Medical Cannabis Program.
If passed, vaporizable dried raw cannabis would be included with the products available to Iowas medical patients. Companies & Iowa Patients Are Hopeful For Change Lucas Nelson, president of MedPharm Iowa, owns and operates Bud & Marys Cannabis in the state. Theres a patient who visits us from just outside of Ottumwa.
Legislation is pending, Senate Bill 165, to establish a medical marijuana access program for qualified patients with a physician’s recommendation to access medical marijuana from licensed retail outlets. It would not allow patients to smoke herbal marijuana or vape, but would allow forms including pills, oils, lozenges and patches.
The agenda includes discussions regarding four newly proposed qualifying debilitating conditions. MCAB is considering Ovarian Cyst, Polycystic Ovarian Syndrome, Uterine Fibroid, and Generalized Anxiety as new qualifying debilitating conditions for medical cannabis patients in Illinois. Monday, June 10, 2024.
The bill allows the department of health to issue permits to medical cannabis dispensaries for the delivery of medical cannabis and cannabis products to qualifying patients or primary caregivers if certain conditions are met. Update : SB 2787 was approved by the Senate Judiciary Committee on 2/25/20. HI resident? New Hampshire.
If the proposal — which was sponsored by Rules Committee Chairman Bill Rabon (R) — is enacted into law, patients who are diagnosed with a “debilitating medical condition” could legally gain access to medical cannabis in North Carolina. Home cannabis cultivation, on the other hand, would be forbidden.
Further, after several failed attempts to legalize medical cannabis, there’s is finally enough steam to put an initiative on the state’s 2024 ballot. 3% THC is legal for treating qualifying health conditions and even recreationally. THC was legalized for qualifying conditions. Like Idaho, CBD with less than.3%
Monday, August 7, and started with introductions from the multitude of members with diverse cannabis-related backgrounds, including nurses, doctors, medical patients, teachers, and more. The medical patient also mentioned the high costs of medicine. The next meeting is scheduled for February 2024.
In an opinion piece published in The Times today , Conservative MP Dan Poulter, a practising NHS doctor, wrote that the drug has a lot of medical benefits – including the treatment of chronic pain, reduction of nausea for patients undergoing chemotherapy, and as a therapy for poor sleep and anxiety disorders.
Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. By 2024, the medicinal cannabis market within the United Kingdom is predicted to be worth nearly US$1.3 in real terms to £4.97
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.
Quemarr’s transformative approach to diabetes treatment offers patients a less intrusive alternative to conventional insulin treatments. The app features a consumption dashboard and a journal section, which will help medical cannabis patients to track their symptom relief. See you in 2024!
Medical cannabis is already incredibly popular in the Sunshine State with 862,155 registered patients according to the latest Florida Department of Health’s Office of Medical Marijuana Use report. So, which state is next to embrace recreational cannabis? All signs point to Florida!
Requires the Department of Agriculture to issue an additional 30 craft grower licenses on or before May 1, 2023 and an additional 30 craft grower licenses on or before September 1, 2024 under specified conditions. To qualify and receive a medical patient card at a discounted rate, visit here.
After all, it is the regulators and health care practitioners that will dictate the ease of patient access in medical markets, not the ever-changing market estimates of size, patients and value provided by third party publishers who all gain their data from the same official and semi official sources.
Ohio’s Cannabis Landscape: Current Status and Future Outlook Ohio’s medical marijuana program, first launched in 2016 , brought legal access to patients managing certain debilitating conditions, but it took three years for dispensaries to open up due to regulatory challenges. Passions run deep on both sides.
Should citizen petition Initiative 65 pass, qualifying patients with one of 22 qualifying conditions would have legal access to cannabis. Predictions also suggest that the state of Mississippi would stand to see revenue from medical cannabis sales reach the $750-$850 million mark as early as 2024.
By engaging individuals across various age groups and demographics, we gather insights into usage patterns, medical conditions, past substance experiences, and more. What Conditions Does Gen Z Use Cannabis To Treat? This approach ensures that we deliver a top-notch service tailored to meet the diverse needs of our customers.
Advocates now have turned their sights to the 2024 election cycle. As far back as 2015, Georgia established a Low THC Oil Patient Registry , which allowed qualified patients to possess cannabis oil with a total THC content of not more than 5%. Until 2019, however, no law provided a way to access that oil.
This statewide change follows New York City ’s April 2019 ban on pre-employment cannabis testing, which deems screening for marijuana or THC as a condition of employment to be an unlawful discriminatory practice, with limited exceptions. Other jurisdictions are catching up to the marijuana law frenzy.
With respect to medical cannabis policies, numerous legislatures took steps in 2021 to expand patients’ access to marijuana products. These actions included expanding the pool of patients eligible for medical cannabis, expanding the number of licensed providers, and easing pathways for patients to obtain a medical marijuana recommendation.
7, 2023) started with introductions from a multitude of members with diverse cannabis-related backgrounds, including nurses, doctors, medical patients, teachers, and more. Before adjourning, two medical patients spoke to MCAB and gave suggestions for improvement for the program with personal anecdotes. The inaugural meeting (Aug.
Most Philadelphia employers are now prohibited from requiring prospective employees to undergo testing for the presence of marijuana as a condition of employment. Retail sales will not begin until January 1, 2024. Currently, only New York City and Nevada have similar marijuana testing restrictions. Takeaways for Employers.
Georgia law allows qualified medical patients to use cannabis products with low THC levels. To qualify for the program, patients must prove that they have an ailment on the state’s list of qualified conditions. After that, patients must renew their medical card every two years.
The Company’s medical cannabis brand, GreenTec , is distributed nationwide to qualified patients through its GreenTec Medical website and various licensed partners. Trading will commence on July 12, 2021. Concurrent with the graduation to the TSX, the Company also expects to change its name to “Avant Brands Inc.”.
After Germany announced plans to legalize the plant, Czechia followed suit, with the first draft of legislation expected early in the 2023 session and tentative legalization in 2024. Product is sold to people with prescriptions at pharmacies and patients can possess up to 180 grams of “dry matter” per month. Possible penalties.
Khiron in the United Kingdom The company is pursuing a consistent approach to improve patient access to medical cannabis and to develop the market for medical cannabis treatments in the UK. Both virtual and in-person appointments can be made via the website www.zereniaclinic.co.uk.
Along with the increasing acceptance of cannabis , the state has witnessed a surge in convenient delivery services, bringing the plant’s benefits directly to patients’ doorsteps. It’s a development that promises to streamline operations for cannabis delivery companies and enhance accessibility for patients.
Apparently, HHS was interested in the experiences of medical marijuana users, and how cannabis helped them with their conditions. GEORGIA Earlier this fall, we noted that independent pharmacies in Georgia would begin offering low THC oil to medical marijuana patients. We’ve not heard the last of this, for sure.
cannabis legalization (or Tilray’s waiver of such condition).In cannabis legalization (or Tilray’s waiver of such condition).In market conditions, future strategic planning, the business and prospects of the MedMen and any other factors that Tilray or the SPV, as applicable, may consider relevant from time to time.?.
billion by 2024. Prohibition Partners’ has also estimated that up to 1 per-cent of the UK population could qualify as medical cannabis patients by 2028. Initially, Farmako Limited will pursue the import of Bedrocan products from the Netherlands to the UK for end patient distribution.
cannabis legalization (or Tilray’s waiver of such condition).In Simon, Tilray’s Chairman and CEO, said, “Backed by accelerating trends towards legalization globally, we are focused on building the world’s leading cannabis-focused consumer branded company with a goal of $4 billion of revenue by the end of our fiscal 2024.
SB 1186– Medicinal Cannabis Patients’ Right of Access Act. The bill’s author, Senator Scott Weiner, states this bill is a victory for seniors living with chronic illness, and will both improve patient access and help fill voids throughout the state where no cannabis license types have been authorized.
MJ Biz run the “New data reveals top medical conditions for which cannabis is reimbursed in Germany” story. 1 followed by a muscle condition known as spasticity. New data reveals top medical conditions for which cannabis is reimbursed in Germany. The firm projects this figure will rise to 7.5 billion euros in 2028.
That move made it easier for patients to obtain medical cards. You can look at the demographics and see how many people are approaching the plant with something in mind; with joint pain, anxiety, with trying to manage a condition. billion in annual medical and recreational cannabis sales by 2024. 1, 2024, start.
The first path, that of traditional medicine, currently offers patients limited options. The bill mandates that by January 2, 2024, Washington shall begin accepting license applications for the manufacture of psilocybin products, operation of psilocybin service centers, facilitation of psilocybin services, and testing of psilocybin products.
Most Philadelphia employers are now prohibited from requiring prospective employees to undergo testing for the presence of marijuana as a condition of employment. Retail sales will not begin until January 1, 2024. Currently, only New York City and Nevada have similar marijuana testing restrictions. Takeaways for Employers.
from the second half of 2021 onwards as the Group fully repaid in May and June 2021 its 2022 and 2023 Eurobonds and successfully purchased a significant portion of its 2024 and 2026 Eurobonds which were bearing much higher interest rates. Second investment grade credit rating from Fitch Ratings after the one secured with Moody’s last year.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content